Sign In
Buy DVAX
$15.50
+0 (+0%)
At Close: May 08, 2026
Envestnet Portfolio Solutions Inc. Purchases 28,846 Shares of Dynavax Technologies Corporation $DVAX
04:40am, Thursday, 23'rd Oct 2025
Envestnet Portfolio Solutions Inc. lifted its position in Dynavax Technologies Corporation (NASDAQ: DVAX) by 214.2% in the undefined quarter, according to its most recent Form 13F filing with the Secu
Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025
04:01pm, Wednesday, 22'nd Oct 2025
EMERYVILLE, Calif. , Oct. 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wil
Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profile Newly presented data outline robust polyfunctional CD4+ T-cell responses in Z-101
3 Of My Favorite Biotech Stocks Under $10
01:15pm, Monday, 29'th Sep 2025
Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited
Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference
04:05pm, Wednesday, 27'th Aug 2025
EMERYVILLE, Calif. , Aug. 27, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, to
Dynavax's shingles vaccine shows similar immune response to GSK's shot in study
08:22am, Thursday, 21'st Aug 2025
Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in early-to-mid-s
Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile
08:00am, Thursday, 21'st Aug 2025
At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited local and systemic post-injection
Dynavax Technologies: A Dip To Accumulate
08:41am, Monday, 11'th Aug 2025
Dynavax delivered strong Q2 results, beating expectations and narrowing guidance, and Heplisav-B continued to sport market share gains and profitability. Heplisav-B is best-in-class in its niche, and
Dynavax Technologies Corporation (DVAX) Q2 2025 Earnings Call Transcript
10:51pm, Thursday, 07'th Aug 2025
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Donn Casale - Senior VP & Chief Commercial Officer Kelly MacDonald - Sen
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates
06:10pm, Thursday, 07'th Aug 2025
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.08 per share a year ago.
Dynavax (DVAX) Q2 Revenue Jumps 29%
05:25pm, Thursday, 07'th Aug 2025
Dynavax (DVAX) Q2 Revenue Jumps 29%
Dynavax Reports Second Quarter 2025 Financial Results
04:00pm, Thursday, 07'th Aug 2025
Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growth Refines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million,
Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
04:02pm, Tuesday, 29'th Jul 2025
EMERYVILLE, Calif. , July 29, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wil
Dynavax elects all four of its nominees after Deep Track proxy fight
12:14pm, Wednesday, 11'th Jun 2025
Biopharmaceutical company Dynavax Technologies on Wednesday defeated investment firm Deep Track Capital's effort to unseat directors when investors re-elected all four candidates, the company said.
Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting
11:01am, Wednesday, 11'th Jun 2025
EMERYVILLE, Calif. , June 11, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercia
